Stryker’s OptaBlate Bone Tumor Ablation System Cleared by FDA

September 20, 2022—Stryker announced that its OptaBlate bone tumor ablation system received 510(k) clearance from the FDA. OptaBlate is Stryker’s first interventional oncology technology.

As part of Stryker's Interventional Spine (IVS) portfolio of vertebral augmentation and radiofrequency ablation technology, ObtaBlate completes its portfolio of treatments for metastatic vertebral body fractures.

Stryker’s IVS business will introduce the OptaBlate at NASS 2022, the 37th annual meeting of the North American Spine Society on October 12-15 in Chicago, Illinois.

According to the company, the device is designed to optimize all aspects of the procedure—from set-up to ablation. Featuring four probes and Stryker’s microinfusion technology, OptaBlate allows physicians to easily customize their procedure and reduce ablation time by 3 minutes.

Stryker outlined key features of the system as follows:

• Treatment of two vertebral body levels at once using a bipedicular approach
• Quicker, more consistent ablation
• Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring

Anthony Brown, MD, a vascular and interventional radiologist at Radiology Imaging Associates in Denver, Colorado, commented in the company’s press release, “Stryker’s new bone tumor ablation system is a significant improvement on existing technology and builds on Stryker's IVS portfolio. There is no more deserving patient population for our attention and intervention. OptaBlate will change lives.”